ClinicalTrials.gg

Sumitomo Pharma Co., Ltd. clinical trials

Also known as Sumitomo Dainippon Pharma.

Part of Sumitomo Chemical Co., Ltd., which holds 51.76% as of 2026-03-31. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 273 studies whose lead sponsor is Sumitomo Pharma Co., Ltd. or one of 8 companies grouped under it. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.

Our grouping of 9 registry names, not the registry’s. See them and correct one ↓

Compare Sumitomo Pharma with Hoffmann-La Roche and Bayer →

Pipeline: 4 programs

Each counted once: 4 with a study Sumitomo Pharma Co., Ltd. leads registered in the last two years.

  • Phase 2

The 4 programs — sign in to see the list, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Sumitomo Pharma Co., Ltd.’s own registered studies; Sumitomo Pharma Co., Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Sumitomo Pharma Co., Ltd.’s studies test, most open studies first — 39 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 39; every drug is on its own page, and each page lists its sponsors.

Coming up

4 of Sumitomo Pharma Co., Ltd.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. M
  6. 1A
  7. 1M
  8. 1J
  9. J
  10. A
  11. 1S
  12. O
  13. N

Add all 4 to your calendar (.ics) → With an account.

All 273 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now93%
  • Under way, not recruiting31%
  • Completed22984%
  • Stopped early3212%Terminated 29 · Withdrawn 3

Phase

  • Phase 3118
  • Phase 182
  • Phase 264
  • Phase 416
  • Early Phase 11

Where

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 2515
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 226

By the year each study started; 48 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Sumitomo Pharma Co., Ltd..

  • Sumitomo Pharma America, Inc.
    Acquired — became part of Sumitomo Pharma Co., Ltd., Oct 14, 2009 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    181 studies →
  • Sumitomo Pharma Co., Ltd.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    25 studies
  • Sumitomo Pharma Switzerland GmbH
    Acquired — became part of Sumitomo Pharma Co., Ltd., Dec 27, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    15 studies →
  • Sumitomo Pharma (Suzhou) Co., Ltd.
    Divested — left Sumitomo Pharma Co., Ltd., Jul 31, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    13 studies →
  • Urovant Sciences GmbH
    Acquired — became part of Sumitomo Pharma Co., Ltd., Dec 27, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    11 studies →
  • Myovant Sciences GmbH
    Acquired — became part of Sumitomo Pharma Co., Ltd., Dec 27, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    11 studies →
  • Sunovion Respiratory Development Inc.
    Acquired — became part of Sumitomo Pharma Co., Ltd., Sep 5, 2012 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    10 studies →
  • Altavant Sciences GmbH
    Acquired — became part of Sumitomo Pharma Co., Ltd., Dec 27, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Dainippon Sumitomo Pharma Europe LTd.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions Sumitomo Pharma Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 273. Browse all 273 →